--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

FDA’s boxed warning on denosumab follows study results showing increased and early risks of severe hypocalcemia in patients on dialysis. The Food and Drug Administration (FDA) has added a new boxed ...

SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan's The Searle Company Limited (PSX: SEARL, ...

Amgen (NASDAQ:AMGN) announced new data supporting its FDA-approved osteoporosis therapy Prolia (Denosumab) on Monday, highlighting its potential against oral alendronate, a commonly-used medication to ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a boxed warning stating denosumab increases severe hypocalcemia risk for adults with advanced CKD ...

SHANGHAI, Dec. 16, 2025 /PRNewswire/ -- Mabwell (688062), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of ...

[email protected]. Question: My new doctor says that my Prolia shot will be very expensive. When my previous physician gave me the shot it was covered in full. Why the difference in cost?

THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S.